

Application No. 09/242,772  
Paper dated September 29, 2005  
In reply to USPTO correspondence of June 29, 2005  
Attorney Docket No. 3374-990278

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

Claims 1-52. (Canceled).

Claim 53. (Previously Presented) An isolated nucleic acid sequence consisting of 7313 base pairs as provided in SEQ ID NO. 116, with an open reading frame of 1500 base pairs starting with the ATG at position 481-483 as provided in SEQ ID NO. 116, wherein said open reading frame encodes for a pleomorphic adenoma gene 1 (PLAG1) protein.

Claim 54. (Currently Amended) An isolated hybrid nucleic acid sequence consisting of a fragment of the isolated nucleic acid sequence according to claim 53 fused to a nucleic acid sequence comprised of a CTNNB1 translocation partner of PLAG1, wherein the presence of said isolated hybrid nucleic acid sequence contains 509 base pairs corresponding to exon 1 of CTNNB1 fused to exons 3 to 5 of PLAG1, and further wherein said isolated hybrid nucleic acid sequence allows the diagnosis of a cell containing said hybrid nucleic acid sequence as a tumor cell.

Claim 55. (Currently Amended) An isolated hybrid nucleic acid sequence consisting of the isolated nucleic acid sequence according to claim 54 fused to wherein said translocation partner is a CTNNB1 protein translocation partner of PLAG1, wherein said isolated hybrid nucleic acid sequence contains 614 base pairs corresponding to exon 1 of CTNNB1 fused to exons 2 to 5 of PLAG1, and further wherein said isolated hybrid nucleic acid sequence allows the diagnosis of a cell containing said hybrid nucleic acid sequence as a tumor cell.

Claim 56-58. (Canceled)